DC cell Vaccine
Phase 1Vaccine
DC cell Vaccine is one of 55 biologic programs targeting Solid Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
137 competitors in Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Lynparza
AstraZenecaPhase 3
Lenvima
EisaiPhase 3
Taxol
TevaPhase 2
Gemzar
Johnson & JohnsonPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Beyfortus
BeiGenePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Tumors1 trial
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT06477614·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DC cell Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details